M
Malcolm Hedgcock
Publications - 5
Citations - 100
Malcolm Hedgcock is an academic researcher. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 1, co-authored 1 publications receiving 5 citations.
Papers
More filters
Journal ArticleDOI
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L. Brumme,Francis Mwimanzi,Hope R. Lapointe,Peter K. Cheung,Yu-Ying Sang,Maggie C. Duncan,Fatimah Hassoon Yaseen,Olga Agafitei,Siobhan Ennis,Kurtis Wc Ng,Simran Basra,L Y Lim,Rebecca Kalikawe,S. Speckmaier,Nadia Morán-García,L. Young,Hasenah Ali,Bruce Ganase,Gisele Umviligihozo,F. Harrison Omondi,Kieran Atkinson,Hanwei Sudderuddin,Junine Toy,Paul Sereda,L. Burns,Cecilia T. Costiniuk,Curtis Cooper,Aslam H. Anis,Victor C. M. Leung,D. Holmes,Mari L. DeMarco,Janet Simons,Malcolm Hedgcock,Marc G. Romney,Rolando Barrios,Silvia Guillemi,Chanson J. Brumme,Ralph Pantophlet,Julio S. G. Montaner,Masahiro Niikura,Marianne Harris,Mark Hull,Mark A. Brockman +42 more
TL;DR: In this article , the authors measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD), ACE2 displacement and viral neutralization activities one month following the first and second COVID-19 vaccine doses, and again 3 months following the second dose, in 100 adults living with HIV and 152 controls.
Journal ArticleDOI
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hope R. Lapointe,Francis Mwimanzi,Peter K. Cheung,Yu-Ying Sang,Fatimah Hassoon Yaseen,Gisele Umviligihozo,Rebecca Kalikawe,S. Speckmaier,Nadia Morán-García,Sneha Datwani,Maggie C. Duncan,Olga Agafitei,Siobhan Ennis,L. Young,Hasenah Ali,Bruce Ganase,Fredrick H. Omondi,Winnie Dong,Junine Toy,Paul Sereda,L. Burns,Cecilia T. Costiniuk,Curtis Cooper,Aslam H. Anis,Victor C. M. Leung,D. Holmes,Mari L. DeMarco,Janet Simons,Malcolm Hedgcock,Natalie Prystajecky,Christopher F. Lowe,Ralph Pantophlet,Marc G. Romney,Rolando Barrios,Silvia Guillemi,Chanson J. Brumme,Julio S. G. Montaner,Mark Hull,Marianne Harris,Masahiro Niikura,Mark A. Brockman,Zabrina L. Brumme +41 more
TL;DR: PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination, which underscore the immune benefits of third doses in light of Omicron.
Posted ContentDOI
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hope R. Lapointe,Francis Mwimanzi,Peter K. Cheung,Yu-qi Sang,Fatimah Hassoon Yaseen,Gisele Umviligihozo,Rebecca Kalikawe,S. Speckmaier,Nadia Morán-García,Sameer Datwani,Maggie C. Duncan,Olga Agafitei,Siobhan Ennis,L. Young,Hasenah Ali,Bruce Ganase,Fredrick H. Omondi,Weiyan Dong,Junine Toy,Paul Sereda,L. Burns,Cecilia T. Costiniuk,Caroline Cooper,Adly Anis,Victor C. M. Leung,D. Holmes,Monica Demarco,Janet Simons,Malcolm Hedgcock,Natalie Prystajecky,Christopher F. Lowe,Ralph Pantophlet,Marc G. Romney,Rolando Barrios,Silvia Guillemi,Chanson J. Brumme,J. S. G. Montaner,Mark Hull,Max Harris,Masahiro Niikura,Mark A. Brockman,Zabrina L. Brumme +41 more
TL;DR: PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination, which underscore the immune benefits of third doses in light of Omicron.
Journal ArticleDOI
38. Anal cancer screening in HIV primary care: uptake and outcomes
Irving E. Salit,Sandra Blitz,Sandra Blitz,Evan Collins,Evan Collins,Banita Aggarwal,Janet Raboud,Janet Raboud,Jill Tinmouth,Jill Tinmouth,Colin Kovacs,Denis Conway,Malcolm Hedgcock,Barry Merkley,David Fletcher,Liviana Calzavara +15 more
TL;DR: In this sample of HIV+ MSM, about half of those invited for anal cancer screening agreed to have it done, and IRC was more successful than TCA at ablating high-grade disease.
Journal ArticleDOI
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
Hope R. Lapointe,Francis Mwimanzi,Peter K. Cheung,Yu-Ying Sang,Fatimah Hassoon Yaseen,S. Speckmaier,E. Barad,Nadia Morán-García,Sneha Datwani,Maggie C. Duncan,Rebecca Kalikawe,Siobhan Ennis,L. Young,Bruce Ganase,Fredrick H. Omondi,Gisele Umviligihozo,Winnie Dong,Junine Toy,Paul Sereda,L. Burns,Cecilia T. Costiniuk,Curtis Cooper,Aslam H. Anis,Victor C. M. Leung,D. Holmes,Mari L. DeMarco,Janet Simons,Malcolm Hedgcock,Natalie Prystajecky,Christopher F. Lowe,Marc G. Romney,Rolando Barrios,Silvia Guillemi,Chanson J. Brumme,Julio S. G. Montaner,Mark Hull,Marianne Harris,Masahiro Niikura,Mark A. Brockman,Zabrina L. Brumme +39 more
TL;DR: In this paper , the authors quantified wild-type-specific, Omicron BA.1-specific and OmicRON BA.5-specific responses up to 6 months post-third dose in 64 PWH and 117 controls who remained COVID-19-naive or experienced their first SARS-CoV-2 infection during this time.